A new study shows strong alignment between real-world outcomes and those seen in clinical trials among a broad population of patients with relapsed or refractory multiple myeloma. In the first study to report real-world outcomes from ciltacabtagene autoleucel (cilta-cel), a chimeric antigen receptor (CAR)-T therapy for multiple myeloma, patients experienced efficacy and safety results similar to those seen in clinical trials, according to new results.
